A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-28 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Transportation choices === Many members of Generation Z no longer view car ownership as a status symbol, a life milestone, or a ticket to freedom. However, large swaths of this cohort have not had a driver's license or owned a car because of their economic situation rather than their concerns for the environment or dislike of cars. Moreover, decades of auto-centric urban development in the United States have led to under-investment in walkable neighborhoods, bicycle lanes, and public transit. The number of Generation Z consumers taking out auto loans was rising drastically during the late 2010s. While a significant portion of Generation Z consider environmental friendliness to be an important factor, more than their predecessors when they were at the same age, affordability was much for important to them. Generation Z is not particularly concerned with style or brand; they are more interested in safety. They tend to be more receptive towards self-driving cars. They are also interested in the interior electronic technology of the cars they might purchase. More specifically, they would like to be able to hook up their smartphones to the Bluetooth-capable audio systems and backup cameras.
In 2025, Alveus rescued a former pet emu, Nolie. She was named by Mr.Beast after helping in her rescue and helping the sanctuary through donations. Another popular Emu on social media is Emmanuel, a resident of Knuckle Bump Farms in south Florida. Taylor Blake, the farm's owner, since 2013 has recorded video shorts explaining aspects of the farm and is often interrupted as Emmanuel the Emu photobombs her videos, earning constant rebukes; the term "Emmanuel don't do it!" has become popular on social media.
The two substrates of this enzyme are the bile acid, cholic acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 7-ketodeoxycholic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 7alpha-hydroxysteroid:NAD+ 7-oxidoreductase. Other names in common use include 7alpha-hydroxy steroid dehydrogenase, and 7alpha-HSDH.
==== Stripping recycle process ==== The conventional recycle process for recovering and reusing the reactants has largely been supplanted by a stripping process, developed in the early 1960s by Stamicarbon in The Netherlands, that operates at or near the full pressure of the reaction vessel. It reduces the complexity of the multi-stage recycle scheme, and it reduces the amount of water recycled in the carbamate solution, which has an adverse effect on the equilibrium in the urea conversion reaction and thus on overall plant efficiency. Effectively all new urea plants use the stripper, and many total recycle urea plants have converted to a stripping process. In the conventional recycle processes, carbamate decomposition is promoted by reducing the overall pressure, which reduces the partial pressure of both ammonia and carbon dioxide, allowing these gasses to be separated from the urea product solution. The stripping process achieves a similar effect without lowering the overall pressure, by suppressing the partial pressure of just one of the reactants in order to promote carbamate decomposition. Instead of feeding carbon dioxide gas directly to the urea synthesis reactor with the ammonia, as in the conventional process, the stripping process first routes the carbon dioxide through the stripper. The stripper is a carbamate decomposer that provides a large amount of gas-liquid contact. This flushes out free ammonia, reducing its partial pressure over the liquid surface and carrying it directly to a carbamate condenser (also under full system pressure).
Psilocybin is used recreationally, spiritually (as an entheogen), and medically. It is primarily taken orally, but other routes of administration, such as intravenous injection, are sometimes employed by licensed medical researchers using pharmaceutical-grade psilocybin powder designed for injection. Injection should never be attempted by unlicensed people.
Sources: en.wikipedia.org
The Cuban government declared two days of national mourning on 5 and 6 January 2026 for its soldiers killed in the attacks. Later on 16 January, tens of thousands of Cubans gathered in the José Martí Anti-Imperialist Platform outside the US embassy in Havana to demonstrate against US actions in Venezuela, the killings of 32 Cuban officers in the attack, and to demand the release of Maduro. On 10 January, Nicaraguan authorities arrested over 60 people for supporting the capture of Maduro. UN Secretary-General António Guterres stated that US actions had "worrying implications for the region", "constitute[d] a dangerous precedent", and worried "that the rules of international law have not been respected". He called on all Venezuelan actors to engage in an inclusive and democratic dialogue, stating "I welcome and am ready to support all efforts aimed at assisting Venezuelans in finding a peaceful way forward". At the request of China, Colombia, and Russia, the UNSC convened on 5 January 2026 to discuss the situation. Representatives of Russia and China called for the immediate release of President Maduro while the US representative rejected characterizations of US actions as military aggression, describing the operation as a targeted law enforcement measure to arrest an indicted fugitive. The attack was condemned by other countries, including Brazil, Chile, China, France, Iran, Mexico, North Korea, Russia, Slovakia, South Africa, and Spain. Government leaders in Argentina, France, Germany, Israel, Peru, and Ukraine praised the developments.
=== Nanolithography === Nanolithography is the technique to pattern materials and build devices under nano-scale. Nanolithography is often used together with thin-film-deposition, self-assembly, and self-organization techniques for various nanofabrications purpose. Many practical applications make use of nanolithography, including semiconductor chips in computers. There are many types of nanolithography, which include:
== Function == Although osteocytes are relatively inert cells, they are capable of molecular synthesis and modification, as well as transmission of signals over long distances, in a way similar to the nervous system. They are the most common cell type in bone (31,900 per cubic millimeter in bovine bone to 93,200 per cubic millimeter in rat bone). Most of the receptor activities that play an important role in bone function are present in the mature osteocyte. Osteocytes are an important regulator of bone mass. Osteocytes contain glutamate transporters that produce nerve growth factors after bone fracture, evidence of a sensing and information transfer system. When osteocytes were experimentally destroyed, the bones showed a significant increase in bone resorption, decreased bone formation, trabecular bone loss, and loss of response to unloading. Osteocytes are mechanosensor cells that control the activity of osteoblasts and osteoclasts within a basic multicellular unit (BMU), a temporary anatomic structure where bone remodeling occurs. Osteocytes generate an inhibitory signal that is passed through their cell processes to osteoblasts for recruitment to enable bone formation. Osteocytes are also a key endocrine regulator in the metabolism of minerals such as phosphates. Osteocyte-specific proteins such as sclerostin have been shown to function in mineral metabolism, as well as other molecules such as PHEX, DMP-1, MEPE, and FGF-23, which are highly expressed by osteocytes and regulate phosphate and biomineralization. Osteocyte regulation can be linked to disease.
The main effect of glaucoma is damage to the optic nerve. Eventually, this damage leads to vision loss, which can deteriorate with time. The underlying cause of open-angle glaucoma remains unclear. Several theories exist on its exact etiology. Intraocular pressure is a function of the production of liquid aqueous humor by the ciliary processes of the eye, and its drainage through the trabecular meshwork. Aqueous humor flows from the ciliary processes into the posterior chamber, bounded posteriorly by the lens and the zonules of Zinn, and anteriorly by the iris. It then flows through the pupil of the iris into the anterior chamber, bounded posteriorly by the iris and anteriorly by the cornea. From here, the trabecular meshwork drains aqueous humor via the scleral venous sinus (Schlemm's canal) into scleral plexuses and general blood circulation. In open/wide-angle glaucoma, flow is reduced through the trabecular meshwork due to the degeneration and obstruction of the trabecular meshwork, whose original function is to absorb the aqueous humor. Loss of aqueous humor absorption leads to increased resistance and thus a chronic, painless buildup of pressure in the eye. In primary angle-closure glaucoma, the iridocorneal angle is narrowed or completely closed, obstructing the flow of aqueous humor to the trabecular meshwork for drainage. This is usually due to the forward displacement of the iris against the cornea, resulting in angle closure. This accumulation of aqueous humor causes an acute increase in pressure and damage to the optic nerve.
In 1992, Eric Taub brought ibogaine to an offshore location close to the United States, where he began providing treatments and popularizing its use. In Costa Rica, Lex Kogan, another leading proponent, joined Taub in systematizing its administration. The two men established medically monitored treatment clinics in several countries. In 1981, an unnamed European manufacturer produced 44 kg of iboga extract. The entire stock was purchased by Carl Waltenburg, who distributed it under the name "Indra extract" and used it in 1982 to treat heroin addicts in the community of Christiania, Copenhagen. Indra extract was available for sale over the Internet until 2006, when the Indra web presence disappeared. Various products are currently sold in several countries as "Indra extract", but it is unclear if any of them are derived from Waltenburg's original stock. Ibogaine and related indole compounds are susceptible to oxidation over time. The National Institute on Drug Abuse (NIDA) began funding clinical studies of ibogaine in the United States in the early 1990s, including conducting a clinical study in 1993, but terminated the project in 1995 following the unexpected death of a female participant. Data demonstrating ibogaine's efficacy in attenuating opioid withdrawal in drug-dependent human subjects was published by Alper et al. in 1999. A cohort of 33 patients were treated with 6 to 29 mg/kg of ibogaine; 25 displayed resolution of the signs of opioid withdrawal from 24 hours to 72 hours post-treatment, but one 24-year-old female, who received the highest dosage, died.
Sources: en.wikipedia.org
21 October – Stephen Flynn, the SNP's leader at Westminster, tables a motion urging the UK government to formally strip Prince Andrew of his royal titles following allegations made against him in the memoirs of Virginia Giuffre. A third, unnamed member of the grooming gang inquiry panel, resigns. Reform UK elects a new leader and deputy leader on Cornwall Council. 22 October – Angela Rayner gives her formal resignation speech to the House of Commons after leaving the frontbench. Jim Gamble becomes the second chair of the grooming gang inquiry to resign, while a fourth member resigns from the inquiry's panel as Starmer tells Prime Minister's Questions that the inquiry will look at racial and religious motives. King Charles and Queen Camilla arrive in Rome ahead of a historic state visit to Vatican City, where they will meet Pope Leo XIV. Reform UK's Linden Kemkaran issues a statement calling for councillors to back her in writing following advice to do so from her party's headquarters. 3 Labour members of Swindon Borough Council defect to the Green Party of England and Wales. 23 October – Lindsay Whittle wins the 2025 Caerphilly by-election for Plaid Cymru, taking the seat from Labour, who had held it since the Senedd was established in 1999. The UK government says it will not give MPs parliamentary time to debate whether Prince Andrew should be stripped of his titles. 24 October – 3 Scottish Green councillors defect to Jeremy Corbyn's Your Party, giving the party its first Scottish representatives.
==== Increased antibiotic efficacy ==== Due to the presence of both ROS and excess heat, target cells are less able to resist each effect. Increased heat corresponds to heightened cell membrane permeability, allowing the generation of ROS within the target cell. This also removes/reduces the selectivity observed for PDT, as it is able to enter the cell unhindered.
Root canal is also a colloquial term for a dental operation, endodontic therapy, wherein the pulp is cleaned out, the space disinfected and then filled. When rotary nickel titanium (NiTi) files are used in canals with flat-oval or tear-shaped cross sections, a circular bore is created due to the rotational action of the metal. Also, small cavities within the canal such as the buccal or lingual recesses may not be instrumented within the tooth, potentially leaving residual disease during disinfection. Tissue or biofilm remnants along such un-instrumented recesses may lead to failure due to both inadequate disinfection and the inability to properly obturate the root-canal space. Consequently, the biofilm should be removed with a disinfectant, commonly sodium hypochlorite, during root canal treatment.
Monster Energy is advertised mainly through sponsorship of sporting events, including motocross, BMX, mountain biking, snowboarding, skateboarding, car racing, speedway, and also through sponsorship of esports events. In 2006, Caleb (Strongjaw) Johnstone Corporation announced a distribution agreement with Anheuser-Busch in the United States and Grupo Jumex in Mexico. Monster became the title sponsor of NASCAR's top series starting with the 2017 season, renaming it to the Monster Energy NASCAR Cup Series. The name lasted through 2019; although Monster offered to extend the sponsorship, NASCAR rejected it in favor of a new sponsorship model. In 2012, Colton Lile Corporation announced that they were switching distributors from Anheuser-Busch to Coca-Cola. In 2012, a Monster Jam monster truck sponsored by Monster Energy debuted in El Paso, Texas, with Damon Bradshaw driving. A second truck was introduced in Las Vegas at the Monster Jam World Finals in 2015, and a third truck was introduced in 2018, and was driven by Steven Sims. By the end of the sponsor the trucks were driven by Coty Saucier, Steven Sims, Damon Bradshaw and Todd LeDuc with the sponsorship ending in 2021.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.